Harvoni Price in India (2023 Prices) | Sunny Pharma

harvoni price in india
In this article you will read about why and how Harvoni price in India is more affordable and not controversial.

The cost of hepatitis C treatment in the United States has been a controversial and highly debated topic in recent years. Hepatitis C is a viral infection that causes liver inflammation, and it can range from a mild illness lasting a few weeks to a serious, lifelong illness. In the past, the main treatment options for hepatitis C were interferon-based therapies, which were associated with significant side effects and low cure rates.

However, the development of new antiviral therapies, such as Harvoni, has significantly improved treatment outcomes and greatly reduced the cost of hepatitis C treatment. Harvoni is a combination of ledipasvir and sofosbuvir, and it has a cure rate of over 95% for most patients.

Despite the effectiveness of these new treatments, the cost of hepatitis C treatment in the United States remains high. In the United States, the price of Harvoni ranges from $63,000 to $94,500 for a 12-week treatment course. This is significantly higher than the price of the drug in other countries, such as India.

India to Rescue Hepatitis C Patients

In India, the price of Harvoni is significantly lower than in the United States. In 2023, the price of Harvoni in India is expected to range from $900 to $1,100 for a 12-week treatment course. This is a fraction of the cost in the United States and makes the treatment more accessible to a larger portion of the population.

There are several reasons why the cost of hepatitis C treatment is significantly lower in India compared to the United States. One reason is that the Indian government has implemented price controls on certain medications, including hepatitis C treatments. In addition, the Indian pharmaceutical industry has a reputation for producing high-quality generic drugs at a lower cost.

However, it is important to note that the lower cost of hepatitis C treatment in India does not necessarily mean that it is more accessible to all patients. India still has a large population living in poverty, and many people may not have the resources or access to healthcare to receive treatment.

You as an American can get access for these hepatitis C treatments at an affordable price.

Takeaway

In conclusion, the cost of hepatitis C treatment, particularly Harvoni, is significantly lower in India compared to the United States. While this may make the treatment more accessible to a larger portion of the population in India, it is important to consider the wider healthcare landscape and ensure that all patients have access to the care they need.